{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:37:57Z","timestamp":1769848677333,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.yebeh.2021.107927","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:39:47Z","timestamp":1617237587000},"page":"107927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Real-world impact of antiepileptic drug combinations with versus without perampanel on healthcare resource utilization in patients with epilepsy in the United States"],"prefix":"10.1016","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2601-6214","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Barghout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Germain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feride","family":"Frech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8002-6838","authenticated-orcid":false,"given":"Craig","family":"Plauschinat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0981-0486","authenticated-orcid":false,"given":"Dominique","family":"Lejeune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Faught","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.107927_b0005","unstructured":"Centers for Disease Control and Prevention. Epilepsy Data and Statistics. 2019 Accesssed on January 16 2020. Available from: https:\/\/www.cdc.gov\/epilepsy\/data\/index.html."},{"key":"10.1016\/j.yebeh.2021.107927_b0010","unstructured":"Epilepsy Foundation. Generalized Seizures. 2016 Accesssed on January 16 2020. Available from: https:\/\/epilepsychicago.org\/epilepsy\/seizure-types\/generalized-seizures\/."},{"issue":"7","key":"10.1016\/j.yebeh.2021.107927_b0015","first-page":"392","article-title":"Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment","volume":"35","author":"Goldenberg","year":"2010","journal-title":"P T"},{"issue":"Suppl. 11","key":"10.1016\/j.yebeh.2021.107927_b0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1528-1167.2005.00403.x","article-title":"Mortality of epilepsy in developed countries: a review","volume":"46","author":"Forsgren","year":"2005","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.yebeh.2021.107927_b0025","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/epi.13857","article-title":"Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States","volume":"58","author":"Faught","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107927_b0030","unstructured":"Center for Disease Control and Prevention. Epilepsy: One of the Nation\u2019s Most Common Neurological Conditions 2017 Accesssed on January 16 2020. Available from: https:\/\/www.cdc.gov\/media\/pdf\/releases\/aag-epilepsy-2017_508c.pdf."},{"issue":"1","key":"10.1016\/j.yebeh.2021.107927_b0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2009.03.003","article-title":"The descriptive epidemiology of epilepsy-a review","volume":"85","author":"Banerjee","year":"2009","journal-title":"Epilepsy Res"},{"issue":"10","key":"10.1016\/j.yebeh.2021.107927_b0040","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Drug-resistant epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.yebeh.2021.107927_b0045","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.yebeh.2021.107927_b0050","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3111\/13696998.2012.751918","article-title":"Antiepileptic drug treatment patterns and economic burden of commercially-insured patients with refractory epilepsy with partial onset seizures in the United States","volume":"16","author":"Chen","year":"2013","journal-title":"J Med Econ"},{"key":"10.1016\/j.yebeh.2021.107927_b0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.yebeh.2018.05.019","article-title":"Patient characteristics and treatment patterns in patients with newly diagnosed epilepsy: a US database analysis","volume":"85","author":"Faught","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.yebeh.2021.107927_b0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1684\/epd.2015.0739","article-title":"Cognitive impairment in epilepsy: the role of network abnormalities","volume":"17","author":"Holmes","year":"2015","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2021.107927_b0065","unstructured":"U.S. Food and Drug Administration. Perampanel: highlights of prescribing information2016 January 16, 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/202834s011lbl.pdf."},{"issue":"Suppl 1","key":"10.1016\/j.yebeh.2021.107927_b0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/epi.14456","article-title":"Perampanel: Does it have broad-spectrum potential?","volume":"60","author":"Potschka","year":"2019","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.yebeh.2021.107927_b0075","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/j.yebeh.2021.107927_b0080","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.yebeh.2021.107927_b0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.yebeh.2021.107927_b0090","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.yebeh.2021.107927_b0095","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.yebeh.2021.107927_b0100","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/epi.14044","article-title":"Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307","volume":"59","author":"Krauss","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107927_b0105","doi-asserted-by":"crossref","unstructured":"Wechsler RT, French J, Trinka E et al. Long-term safety and efficacy outcomes of adjunctive perampanel: an open-label extension (OLEx) of a Phase III study in patients with drug-resistant primary generalized tonic-clonic (PGTC) seizures in idiopathic generalized epilepsy (IGE)(P5. 233). Neurology. 2017;88(16 Supplement):P5.233.","DOI":"10.1212\/WNL.88.16_supplement.P5.233"},{"key":"10.1016\/j.yebeh.2021.107927_b0110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/s-0038-1675546","article-title":"Safety and efficacy of perampanel as adjunctive therapy in patients with refractory focal epilepsy over 12 months: clinical experience in a real-world setting","volume":"5","author":"Rinaldi","year":"2018","journal-title":"Int J Epilepsy"},{"issue":"6","key":"10.1016\/j.yebeh.2021.107927_b0115","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/1756285616661115","article-title":"Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data","volume":"9","author":"Rohracher","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"10.1016\/j.yebeh.2021.107927_b0120","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/ane.13061","article-title":"Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain","volume":"139","author":"Strzelczyk","year":"2019","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10.1016\/j.yebeh.2021.107927_b0125","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1212\/WNL.0000000000005756","volume":"91","author":"Kanner","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.yebeh.2021.107927_b0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.14581\/jer.19002","article-title":"Antiepileptic drug therapy in patients with drug-resistant epilepsy","volume":"9","author":"Park","year":"2019","journal-title":"J Epilepsy Res"},{"issue":"14","key":"10.1016\/j.yebeh.2021.107927_b0135","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1080\/14656566.2019.1637420","article-title":"Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus","volume":"20","author":"Willems","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.yebeh.2021.107927_b0140","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","article-title":"Combining antiepileptic drugs\u2013rational polytherapy?","volume":"20","author":"Brodie","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.107927_b0145","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.2147\/DDDT.S122404","article-title":"Spotlight on perampanel in the management of seizures: design, development and an update on place in therapy","volume":"11","author":"Faulkner","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"10.1016\/j.yebeh.2021.107927_b0150","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1111\/epi.14522","article-title":"Perampanel in routine clinical use in idiopathic generalized epilepsy: the 12-month GENERAL study","volume":"59","author":"Villanueva","year":"2018","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.yebeh.2021.107927_b0155","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1212\/WNL.0000000000006751","article-title":"Readmitted after a seizure-related hospitalization: Deja vu","volume":"92","author":"Jette","year":"2019","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.yebeh.2021.107927_b0160","first-page":"e429","article-title":"Readmission after seizure discharge in a nationally representative sample","volume":"92","author":"Blank","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.yebeh.2021.107927_b0165","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.seizure.2014.01.016","article-title":"Management of focal epilepsy in adults treated with polytherapy in France: the direct cost of drug resistance (ESPERA study)","volume":"23","author":"de Zelicourt","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.107927_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106634","article-title":"Risk of hospitalization among patients with epilepsy using long versus short half-life adjunctive antiepileptic drugs","volume":"102","author":"Cramer","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107927_b0175","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.yebeh.2014.03.013","article-title":"The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies","volume":"35","author":"Gidal","year":"2014","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502100161X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502100161X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:38:13Z","timestamp":1761503893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550502100161X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":35,"alternative-id":["S152550502100161X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107927","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world impact of antiepileptic drug combinations with versus without perampanel on healthcare resource utilization in patients with epilepsy in the United States","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107927","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107927"}}